NFKB1 and Parkinson disease: It suppressed iNOS and NF-κB activation in glial cells, prevented astroglial and microglial oxidative injury in ex vivo systems, and inhibited microglial activation in lipopolysaccharide (LPS)–induced Parkinson’s disease (PD) models (Wang et al., 2002).